1-20 of 49
Charles M. Perou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors

Open Access
Hyunsoo Kim, Austin A. Whitman, Kamila Wisniewska, Rasha T. Kakati, Susana Garcia-Recio, Benjamin C. Calhoun, Hector L. Franco, Lisa A. Carey, Charles M. Perou, Philip M. Spanheimer
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (13): 2839.
https://doi.org/10.1158/1078-0432.CCR-25-1944
Published: 01 July 2025
View articletitled, Correction: Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors
Open the PDF for Correction: Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors in another window
Journal Articles

Abstract P4-03-19: Plasma-based prediction of prognosis, receptor status and organ involvement among patients receiving antibody-drug conjugates for metastatic breast cancer

Free
Paolo Tarantino, Morganti, Rosario Vega, Francisco Pardo, Sandra Cobo, Melissa E. Hughes, Ross Kusmick, Kalie Smith, Guillermo Villacampa, Fara Brasó-Maristany, Mercedes Marín-Aguilera, Georgia Suggs, Molly Skeffington, Simone Buck, Kerry Sendrick, Abigail Recko, Katherine Junkins, Hajer Rahoo, Oleguer Castillo, Sarah Sammons, Antonio Giordano, Ana Garrido-Castro, Nabihah Tayob, Charles M. Perou, Joel S. Parker, Patricia Villagrasa, Laia Paré, Nancy U. Lin, Heather Parsons, Ana Vivancos, Aleix Prat, Sara M. Tolaney
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P4-03-19.
https://doi.org/10.1158/1557-3265.SABCS24-P4-03-19
Published: 13 June 2025
View articletitled, Abstract P4-03-19: Plasma-based prediction of prognosis, receptor status and organ involvement among patients receiving antibody-drug conjugates for metastatic breast cancer
Journal Articles

Abstract P5-06-19: Single-cell transcriptional features of human breast tumors and model systems

Free
Julia Altman, Amy L. Olex, Emily K. Zboril, Carson J. Walker, David C. Boyd, Rachel K. Myrick, Nicole S. Hairr, Jennifer E. Koblinski, Madhavi Puchalapalli, Bin Hu, Mikhail G. Dozmorov, X. Steven Chen, Yunshun Chen, Charles M. Perou, Brian D. Lehmann, Jane E. Visvader, J. Chuck Harrell
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P5-06-19.
https://doi.org/10.1158/1557-3265.SABCS24-P5-06-19
Published: 13 June 2025
View articletitled, Abstract P5-06-19: Single-cell transcriptional features of human breast tumors and model systems
Journal Articles

Abstract P2-07-29: DNADX in advanced hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer following endocrine therapy with or without palbociclib: a correlative analysis from the GEICAM/2014-12 FLIPPER phase II randomized trial

Free
Joan Albanell, Aleix Prat, Maria Teresa Martinez, Guillermo Villacampa, Lorena Paris, Sandra Cobo, Miriam O' Connor, Rosario Vega, Luis de la Cruz-Merino, Fara Brasó-Maristany, Ana Santaballa Bertrán, Francisco Pardo, Noelia Martínez-Jañez, Patricia Galván, Fernando Moreno, Oleguer Castillo, Isaura Fernández, Laia Paré, Jesús Alarcón, Judit Matito, Juan Antonio Virizuela, Juan de la Haba-Rodríguez, Pedro Sánchez-Rovira, Lucía González-Cortijo, Mireia Margelí, Alfonso Sánchez-Muñoz, Iria González Maeso, Antonio Antón, Juan Guerra, Ariadna Tibau, Manuel Ruíz-Borrego, Cinta Rosa Albacar, Coralia Bueno, Andrés García-Palomo, Yolanda Fernández, Sonia González, María Rodríguez de la Borbolla, Vega Iranzo, Catherine M Kelly, Maccon M Keane, Patrick G Morris, Conleth G Murphy, Charles M Perou, Jesús Herranz, Joel S Parker, Marta Portela, Patricia Villagrasa, Rosalia Caballero, Ana Vivancos, Federico Rojo
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P2-07-29.
https://doi.org/10.1158/1557-3265.SABCS24-P2-07-29
Published: 13 June 2025
View articletitled, Abstract P2-07-29: DNADX in advanced hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer following endocrine therapy with or without palbociclib: a correlative analysis from the GEICAM/2014-12 FLIPPER phase II randomized trial
Journal Articles

Abstract P1-02-24: Leveraging bulk and single-cell RNA sequencing to identify features predicting response and survival to abemaciclib in six mouse models of breast cancer

Free
Yash Agrawal, Kevin Mott, Tulay Yilmaz-Swenson, Charles M. Perou
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P1-02-24.
https://doi.org/10.1158/1557-3265.SABCS24-P1-02-24
Published: 13 June 2025
View articletitled, Abstract P1-02-24: Leveraging bulk and single-cell RNA sequencing to identify features predicting response and survival to abemaciclib in six mouse models of breast cancer
Journal Articles

Abstract P4-09-19: Exploring cellular heterogeneity of localised breast cancers

Free
Beata Kiedik, Daniel L. Roden, Kate Harvey, Ghamdan Al-Eryani, Sunny Z. Wu, Mun N. Hui, Sandra O’Toole, Elgene Lim, Charles M. Perou, Alexander Swarbrick
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P4-09-19.
https://doi.org/10.1158/1557-3265.SABCS24-P4-09-19
Published: 13 June 2025
View articletitled, Abstract P4-09-19: Exploring cellular heterogeneity of localised breast cancers
Journal Articles

Abstract PS1-05: Genomic characteristics related to histology-based immune features in breast cancer

Free
Yoon Jin, Constandina E. O’Connell, Benjamin C. Calhoun, Christian Brueffer, Christer Larsson, Åke Borg, Lao H. Saal, Charles M. Perou
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): PS1-05.
https://doi.org/10.1158/1557-3265.SABCS24-PS1-05
Published: 13 June 2025
View articletitled, Abstract PS1-05: Genomic characteristics related to histology-based immune features in breast cancer
Journal Articles

Abstract PS12-05: PARP7 inhibition combined with radiotherapy overcomes ICI resistance in breast cancer

Free
Lynn Lerner, Anna M. Goddard, Qinhong Wang, Kevin R. Mott, Charles M. Perou, Gaorav P. Gupta
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): PS12-05.
https://doi.org/10.1158/1557-3265.SABCS24-PS12-05
Published: 13 June 2025
View articletitled, Abstract PS12-05: PARP7 inhibition combined with radiotherapy overcomes ICI resistance in breast cancer
Journal Articles

Abstract PS2-09: Liquid biopsy DNADX assay in advanced ER+/HER2-negative breast cancer after progression on CDK4/6 and aromatase inhibitors: a correlative analysis from the PACE phase II randomized trial

Free
Guilherme Nader-Marta, Rosario Vega-León, Guillermo Villacampa, Reshma Mahtani, Cynthia Ma, Angele DeMichele, Sandra Cobo, Francisco Pardo, Massimo Cristofanilli, Jane Meisel, Kathy D. Miller, Yara Abdou, Elizabeth C. Riley, Ashka Patel, Melissa E. Hughes, Fara Brasó-Maristany, Oleguer Castillo, Patricia Galván, Rubina Qamar, Priyanka Sharma, Laia Paré, Marina Gómez Rey, Judit Matito, Sonya Reid, Michelle DeMeo, Patricia Villagrasa, Charles M. Perou, Joel S. Parker, Ana Vivancos, Yuan Liu, Eric Gauthier, Harold J. Burstein, Sara M. Tolaney, Rinath Jeselsohn, Aleix Prat, Erica L. Mayer
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): PS2-09.
https://doi.org/10.1158/1557-3265.SABCS24-PS2-09
Published: 13 June 2025
View articletitled, Abstract PS2-09: Liquid biopsy DNADX assay in advanced ER+/HER2-negative breast cancer after progression on CDK4/6 and aromatase inhibitors: a correlative analysis from the PACE phase II randomized trial
Journal Articles

Abstract PS4-06: HER2DX ERBB2 mRNA Score in First-Line Metastatic HER2-Positive Breast Cancer Treated with Docetaxel, Trastuzumab and Pertuzumab: Correlative Analysis from CLEOPATRA Phase III Trial

Free
Javier Cortés, Fara Brasó-Maristany, Guillermo Villacampa, Eva Ciruelos, Mercedes Marín-Aguilera, Patricia Galván, Sanne de Haas, Eleonora Restuccia, Mahesh Shivhare, Laia Paré, Wesley Buckingham, Joel S. Parker, Ana Vivancos, Charles M. Perou, Patricia Villagrasa, Julia Maués, Aleix Prat, Sandra Swain
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): PS4-06.
https://doi.org/10.1158/1557-3265.SABCS24-PS4-06
Published: 13 June 2025
View articletitled, Abstract PS4-06: HER2DX ERBB2 mRNA Score in First-Line Metastatic HER2-Positive Breast Cancer Treated with Docetaxel, Trastuzumab and Pertuzumab: Correlative Analysis from CLEOPATRA Phase III Trial
Journal Articles

Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort

Available to Purchase
Xiaopeng Sun, Laura C. Kennedy, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Melinda Sanders, Charles M. Perou, Melissa A. Troester, Justin M. Balko, Sonya A. Reid
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 4077–4081.
https://doi.org/10.1158/1078-0432.CCR-24-1286
Published: 13 September 2024
View articletitled, Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort
Open the PDF for Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort in another window
Includes: Supplementary data
Journal Articles

HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial

Open Access
Antonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany, Laia Paré, Guillermo Villacampa, Maria Gion, Peter Schmid, Marco Colleoni, Manuel R. Borrego, Patricia Galván, Joel S. Parker, Wesley Buckingham, Charles M. Perou, Patricia Villagrasa, Jose A. Guerrero, Miguel Sampayo-Cordero, Mario Mancino, Aleix Prat, Javier Cortés
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 4123–4130.
https://doi.org/10.1158/1078-0432.CCR-24-0464
Published: 13 September 2024
View articletitled, HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial
Open the PDF for HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial in another window
Includes: Supplementary data
Journal Articles

The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer

Available to Purchase
Yoo Jane Han, Siyao Liu, Ashley Hardeman, Padma Sheila Rajagopal, Jeffrey Mueller, Galina Khramtsova, Ayodele Sanni, Mustapha Ajani, Wendy Clayton, Ian W. Hurley, Toshio F. Yoshimatsu, Yonglan Zheng, Joel Parker, Charles M. Perou, Olufunmilayo I. Olopade
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (11): 2609–2618.
https://doi.org/10.1158/1078-0432.CCR-23-1526
Published: 03 June 2024
View articletitled, The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer
Open the PDF for The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors

Open Access
Hyunsoo Kim, Austin A. Whitman, Kamila Wisniewska, Rasha T. Kakati, Susana Garcia-Recio, Benjamin C. Calhoun, Hector L. Franco, Lisa A. Carey, Charles M. Perou, Philip M. Spanheimer
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4894–4907.
https://doi.org/10.1158/1078-0432.CCR-23-1248
Published: 01 December 2023
View articletitled, Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors
Open the PDF for Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors in another window
Includes: Supplementary data
Journal Articles

Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Open Access
Holly Tovey, Orsolya Sipos, Joel S. Parker, Katherine A. Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Anita Grigoriadis, Andrew Tutt, Maggie Chon U. Cheang
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3691–3705.
https://doi.org/10.1158/1078-0432.CCR-23-0370
Published: 15 September 2023
View articletitled, Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
Open the PDF for Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727) in another window
Includes: Supplementary data
Journal Articles

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer

Open Access
Youli Xia, Xiaping He, Lorna Renshaw, Carlos Martinez-Perez, Charlene Kay, Mark Gray, James Meehan, Joel S. Parker, Charles M. Perou, Lisa A. Carey, J. Michael Dixon, Arran Turnbull
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3618–3629.
https://doi.org/10.1158/1078-0432.CCR-21-3189
Published: 15 August 2022
View articletitled, Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
Open the PDF for Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy

Available to Purchase
Tomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarneri, Javier Cortes, Patricia Villagrasa, Núria Chic, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Gaia Griguolo, Antonio Llombart, Pierfranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Paré, Patricia Galvan, Lisa A. Carey, Charles M. Perou, Aleix Prat
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3116–3125.
https://doi.org/10.1158/1078-0432.CCR-20-4102
Published: 01 June 2021
View articletitled, Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy
Open the PDF for Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy in another window
Includes: Supplementary data
Journal Articles

Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer

Free
Erika J. Crosby, Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Kay U. Wagner, William J. Muller, Lewis A. Chodosh, Gloria Broadwater, Terry Hyslop, Jonathan H. Shepherd, Daniel P. Hollern, Xiaping He, Charles M. Perou, Shengjie Chai, Benjamin K. Ashby, Benjamin G. Vincent, Joshua C. Snyder, Jeremy Force, Michael A. Morse, Herbert K. Lyerly, Zachary C. Hartman
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4670–4681.
https://doi.org/10.1158/1078-0432.CCR-20-0389
Published: 01 September 2020
View articletitled, Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Open the PDF for Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer in another window
Includes: Supplementary data
Journal Articles

The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy

Free
Adrienne G. Waks, Daniel G. Stover, Jennifer L. Guerriero, Deborah Dillon, William T. Barry, Evisa Gjini, Christina Hartl, Wesley Lo, Jennifer Savoie, Jane Brock, Robert Wesolowski, Zaibo Li, Adrienne Damicis, Anne V. Philips, Yun Wu, Fei Yang, Amy Sullivan, Patrick Danaher, Heather Ann Brauer, Wafa Osmani, Mikel Lipschitz, Katherine A. Hoadley, Michael Goldberg, Charles M. Perou, Scott Rodig, Eric P. Winer, Ian E. Krop, Elizabeth A. Mittendorf, Sara M. Tolaney
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4644–4655.
https://doi.org/10.1158/1078-0432.CCR-19-0173
Published: 01 August 2019
View articletitled, The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy
Open the PDF for The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Free
Priyanka Sharma, Sara López-Tarruella, José Angel García-Saenz, Qamar J. Khan, Henry L. Gómez, Aleix Prat, Fernando Moreno, Yolanda Jerez-Gilarranz, Agustí Barnadas, Antoni C. Picornell, María del Monte-Millán, Milagros González-Rivera, Tatiana Massarrah, Beatriz Pelaez-Lorenzo, María Isabel Palomero, Ricardo González del Val, Javier Cortés, Hugo Fuentes-Rivera, Denisse Bretel Morales, Iván Márquez-Rodas, Charles M. Perou, Carolyn Lehn, Yen Y. Wang, Jennifer R. Klemp, Joshua V. Mammen, Jamie L. Wagner, Amanda L. Amin, Anne P. O’Dea, Jaimie Heldstab, Roy A. Jensen, Bruce F. Kimler, Andrew K. Godwin, Miguel Martín
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5820–5829.
https://doi.org/10.1158/1078-0432.CCR-18-0585
Published: 03 December 2018
View articletitled, Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Open the PDF for Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel in another window
Includes: Supplementary data